Medical experts have officially renamed polycystic ovary syndrome (PCOS) as polyendocrine metabolic ovarian syndrome (PMOS) following more than a decade of global debate. The change, announced at the European Congress of Endocrinology in Prague, seeks to better reflect the disorder’s widespread impact on the body beyond reproductive health.

The new name, PMOS, emphasizes the polyendocrine and metabolic aspects of the condition, which affects an estimated 1 in 8 females worldwide. Historically, PCOS was narrowly defined by ovarian symptoms, but research shows it influences multiple body systems, including metabolic and endocrine functions. Experts say the rebranding will improve diagnostic clarity and patient care by aligning the name with its true physiological reach.

A decade of global consultation led to the change

The renaming process spanned over 10 years of consultations among endocrinologists, gynecologists, and patient advocacy groups worldwide. The Androgen Excess and PCOS Society, a key organization in the decision, played a central role in gathering input from medical professionals and patients. The society highlighted that the old name often led to misdiagnosis or delayed treatment because it focused primarily on ovarian cysts, a symptom present in only a subset of patients.

Why the new name matters for patients and doctors

The shift from PCOS to PMOS is expected to reduce confusion in clinical settings by emphasizing the disorder’s broader health implications. Common symptoms—such as insulin resistance, obesity, and hormonal imbalances—often go unaddressed under the old name. With PMOS, doctors may prioritize metabolic testing, mental health support, and long-term management strategies more effectively.

Dr. Dorte Glintborg, a leading endocrinologist and member of the task force behind the name change, stated that the new terminology will help bridge gaps in care. “Many patients with PCOS were not getting the right treatment because the name didn’t reflect the full scope of their symptoms,” she said. “PMOS will encourage a more holistic approach.”

What happens next for patients and the medical community

The name change is effective immediately, but widespread adoption will take time. Medical journals, healthcare providers, and insurance systems will need to update their records and diagnostic codes. The Endocrine Society and other global health organizations are expected to endorse the new name in their guidelines within the next year.

For patients, the change may bring clearer explanations about their health and better access to specialized care. Support groups and advocacy organizations are already revising their materials to reflect the new terminology. Experts urge patients to discuss the name change with their doctors to ensure continuity in their treatment plans.

The broader medical community will monitor the impact of the new name on diagnosis rates, treatment outcomes, and patient education. If successful, the PMOS rebranding could set a precedent for how other complex conditions are named in the future.

What You Need to Know

  • Source: Healthline
  • Published: May 16, 2026 at 11:08 UTC
  • Category: Health
  • Topics: #health · #wellness · #medicine · #politics · #usa · #congress

Read the Full Story

This is a curated summary. For the complete article, original data, quotes and full analysis:

Read the full story on Healthline →

All reporting rights belong to the respective author(s) at Healthline. GlobalBR News summarizes publicly available content to help readers discover the most relevant global news.

Curated by GlobalBR News · May 16, 2026

🇧🇷 Resumo em Português

O nome da síndrome que afeta milhões de mulheres brasileiras acaba de mudar após uma década de discussões entre especialistas: o que era conhecido como Síndrome dos Ovários Policísticos (SOP) agora passa a ser chamado de Síndrome Metabólica Poliglandular Ovariana (SMPO). A alteração, anunciada durante o Congresso Europeu de Endocrinologia, reflete uma compreensão mais ampla dos impactos da condição, que vai muito além dos ovários e inclui alterações metabólicas, hormonais e até cardiovasculares.

No Brasil, onde estima-se que cerca de 10% das mulheres em idade reprodutiva convivam com a condição, a mudança de nomenclatura é mais do que uma simples atualização: é um reconhecimento de que a SMPO exige abordagens multidisciplinares, envolvendo ginecologistas, endocrinologistas e cardiologistas. Até então tratada muitas vezes como um problema restrito à ginecologia, a nova classificação pode impulsionar políticas públicas mais eficazes, como programas de prevenção de diabetes e doenças cardíacas, além de reduzir o estigma de que a doença está apenas ligada à infertilidade ou à aparência física.

A partir de agora, médicos e pacientes precisam se adaptar a essa nova realidade, e os próximos passos incluem a atualização de protocolos clínicos e campanhas de conscientização para esclarecer as múltiplas faces da SMPO.

🇪🇸 Resumen en Español

El síndrome de ovario poliquístico, un trastorno hormonal que afecta a millones de mujeres en el mundo, ha cambiado de nombre tras una década de debate médico. Ahora se denominará síndrome metabólico ovárico, una modificación que refleja mejor su impacto en múltiples sistemas del organismo.

La nueva nomenclatura, anunciada durante el Congreso Europeo de Endocrinología, busca subrayar la relación de este cuadro con alteraciones metabólicas como la resistencia a la insulina y el riesgo cardiovascular. Para las hispanohablantes, la medida podría facilitar un diagnóstico más preciso y un enfoque terapéutico integral, ya que el nombre actual, asociado exclusivamente a los ovarios, ha generado confusión. Además, podría impulsar mayor investigación sobre sus causas y tratamientos, mejorando así la calidad de vida de las afectadas.